Stock comparison
Genmab A/S
Merck &
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
MRK
Merck &
Market cap
$302.33B
Sector
Healthcare
Overall winner
Merck & MRK
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | MRK | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 64C | GMAB |
| Benjamin Graham | 64C | 78B | MRK |
| Philip Fisher | 48D | 63C | MRK |
| Peter Lynch | 25F | 68B | MRK |
| Joel Greenblatt | 76B | 34F | GMAB |
| Charlie Munger | 68C | 68C | Tie |
| Terry Smith | 71C | 55D | GMAB |
Side-by-side metrics
| Metric | GMAB | MRK |
|---|---|---|
| Market cap | $16.5B | $302.33B |
| P/E (TTM) | 6.2x | 31.5x |
| EV/EBIT | 12.0x | 13.9x |
| ROIC (TTM) | 43.78% | 13.34% |
| Gross margin | 93.88% | 75.91% |
| Net margin | 18.23% | 13.62% |
| Revenue CAGR 5y | -18.45% | 7.45% |
| EPS CAGR 5y | -23.48% | 9.06% |
| Debt / Equity | 0.1x | 1.1x |
| Dividend yield | 0.0% | 2.91% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- Debt / Equity0.1xvs 1.1x+93%
- P/E (TTM)6.2xvs 31.5x+80%
- ROIC (TTM)43.78%vs 13.34%+70%
- Net margin18.23%vs 13.62%+25%
MRK leads on
- Revenue CAGR 5y7.45%vs -18.45%+140%
- EPS CAGR 5y9.06%vs -23.48%+139%
- Dividend yield2.91%vs 0.0%+100%
- Market cap$302.33Bvs $16.5B+95%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.